We are pleased to inform you that Tejnaksh Healthcare Research lab has been recently renewed approval by the department of Scientific and Industrial Research (DSIR) For the next two years Please ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tejnaksh Healthcare has received a renewed approval from the Department of Scientific and Industrial Research (DSIR) for its in-house research lab. The renewal is valid for the next two years. DSIR recognition is typically given to companies that carry out genuine in-house R&D activities and helps in claiming R&D-related tax benefits and accessing government R&D funding. The announcement does not mention any financial impact, new product, or revenue estimate tied to this renewal.
This is a routine renewal of the company's R&D lab recognition and is unlikely to cause any significant movement in the stock price. It keeps the company's eligibility for R&D tax benefits and government grants intact.